The role of chemotherapy in patients with established gastric cancer

Best Practice and Research: Clinical Gastroenterology

Volumn 20, Issue 4, 2006, Pages 789-799

  Wagner, Anna D ^a   Schneider, Paul M ^b   Fleig, Wolfgang E ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

chemotherapy; gastric or stomach and neoplasm

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLATINUM DERIVATIVE;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG INFUSION; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; META ANALYSIS; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASM STAGING; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 33748678287     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2006.01.002     Document Type: Review

References (50)

1. Wagner A.D., Grothe W., Behl S., et al. Chemotherapy for advanced gastric cancer. The Cochrane Library (2005), Update Software, Oxford Issue 2
2. Murad A.M., Santiago F.F., Petroianu A., et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72 (1993) 37-41
3. Pyrhönen S., Kuitunen T., Nyandoto P., et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71 (1995) 587-591
4. Scheithauer W., Kornek G., Hejna M., et al. Palliative chemotherapy versus best supportive care in patients with metastatic gastric cancer: a randomised trial. Ann Hematol 73 supplement 2 (1996) A181
5. Loehrer Sr. P.J., Harry D., and Chlebowski R.T. 5-fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma. Invest New Drugs 12 (1994) 57-63
6. Cullinan S.A., Moertel C.G., Fleming T.R., et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 253 (1985) 2061-2067
7. Cullinan S.A., Moertel C.G., Wieand H.S., et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol 12 (1994) 412-416
8. Ohtsu A., Shimada Y., Shirao K., et al. Randomised phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21 (2003) 54-59
9. Barone C., Corsi D.C., Pozzo C., et al. Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomised phase II studies. Cancer 82 (1998) 1460-1467
10. Colucci G., Giotta F., Maiello E., et al. Efficacy of the association of folinic acid and 5-fluorouracil alone versus folinic acid and 5-fluorouracil plus 4-epidoxorubicin in the treatment of advanced gastric carcinoma. Am J Clin Oncol 18 (1995) 519-524
11. De Lisi V., Cocconi G., Tonato M., et al. Randomised comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC). Cancer Treat Rep 70 (1986) 481-485
12. Popov I., Svetislav B.J., and Jezdic S.D. Bi-weekly 24-hour infusion of high dose 5-fluorouracil versus EAP regimen in advanced gastric cancer: a randomised phase II study. Ann Oncol 13 supplement 5 (2002) 188
13. Yamamura Y., Miyazaki I., Ogawa M., et al. A randomised controlled trial with methotrexate (MTX), 5-fluorouracil (5-FU) and pirarubicin (THP) vs 5-FU alone in advanced or recurrent gastric carcinoma. Tokai Hokuriku THP Study Group. Gan to Kagaku Ryoho 25 (1998) 1543-1548
14. Levi J.A., Fox R.M., Tattersall M.H., et al. Analysis of a prospectively randomised comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. J Clin Oncol 4 (1986) 1348-1355
15. Kyoto Research Group for Chemotherapy of Gastric Cancer (KRGCGC). A randomised, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin, and 4′-epirubicin (FPEPIR). Anticancer Res 12 (1992) 1983-1988
16. Kim T.W., Choi S.J., Ahn J.H., et al. A prospective randomised phase III trial of 5-fluorouracil and cisplatin (FP) versus epirubicin, cisplatin, and 5-fu (ECF) in the treatment of patients with previously untreated advanced gastric cancer (AGC). Eur J Cancer 37 supplement 6 (2001) S314
17. Ross P., Nicolson M., Cunningham D., et al. Prospective randomised trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20 (2002) 1996-2004
18. Gastrointestinal Tumor Study Group. Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three-arm randomised trial in metastatic gastric cancer. J Natl Cancer Inst 80 (1988) 1011-1015
19. Coccioni G., Bella M., Zironi S., et al. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomised trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 12 (1994) 2687-2693
20. Coccioni G., Carlini P., Gamboni A., et al. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol 14 (2003) 1258-1263
21. Kikuchi K., Wakui A., Shimizu H., et al. Randomised controlled study on chemotherapy with 5-FD, ADM plus CDDP in advanced gastric carcinoma. Gan to Kagaku Ryoho 17 4 Pt 1 (1990) 655-662
22. Roth A., Kolaric K., Zupanc D., et al. High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: a randomised study. Tumori 85 (1999) 234-238
23. Webb A., Cunningham D., Scarffe J.H., et al. Randomised trial comparing epirubicin, cisplatin, and fluouracil versus fluouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15 (1997) 261-267
24. Cunningham D, Rao S, Starling N et al. Randomized multicentre phase III study comparing capecitabine with fluouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: The REAL-2 trial. Proceedings of the American Society of Clinical Oncology 42nd Annual Meeting; 2006 June 2-6; Georgia World Congress Center; Atlanta, GA, USA: 4017.
25. Dank M, Zaluski J, Valvere V et al. Randomised phase III trial of irinotecan (CPT 11) + 5-FU/folinic acid (FA) vs CDDP + 5-FU in first line advanced gastric cancer patients. Proceedings of the American Society of Clinical Oncology 41st Annual Meeting; 2005 May 13-17; Orlando; Florida, USA: 4003.
26. Wagner A.D., Grothe W., Haerting J., et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24 (2006) 2903-2909
27. Moiseyenko VM, Ajani J, Tjulandin SA et al. Final results of a randomised controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Proceedings of the American Society of Clinical Oncology 41st Annual Meeting; 2005 May 13-17; Orlando; Florida, USA: 4002.
28. Sepulveda C., Marlin A., Yoshida T., et al. Palliative care: the World Health Organization's Global Perspective. J Pain Symptom Manage 24 (2002) 91-96
29. Gunderson L.L., and Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series-clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 8 (1982) 1-11
30. Wanebo H.J., Kenedy B.J., and Chmiel J. Cancer of the stomach: a patient case study by the American College of Surgeons. Ann Surg 218 (1993) 583-592
31. Siewert J., Bottcher K., Hubert J., et al. German Gastric Carcinoma Study Group: relevant prognostic factors in gastric cancer- ten year results of the German Gastric Cancer Study. Ann Surg 228 (1998) 449-461
32. Hundahl S.A., Philips J.L., and Menck H.R. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 88 (2000) 921-932
33. Yu W., Seo B.Y., and Chung H.Y. Postoperative body-weight loss and survival after curative resection for gastric cancer. Br J Surg 89 (2002) 467-470
34. Macadam R., Sarela A., Wilson J., et al. Bone marrow micrometastases predict early postoperative recurrence after surgical resection of oesophageal and gastric carcinoma. Eur J Surg Oncol 29 (2003) 450-454
35. Lim L., Michael M., Mann B., et al. Adjuvant therapy in gastric cancer. J Clin Oncol 23 (2005) 6220-6232
36. Maruyama K., Sasako M., Kinoshita T., et al. Should systematic lymph node dissection be recommended for gastric cancer?. Eur J Cancer 34 (1998) 1480-1490
37. Cuscheri A., Weeden S., Fielding J., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomised surgical trial-Surgical Co-Operative Group. Br J Cancer 79 (1999) 1522-1530
38. Bonenkamp J.J., Hermans J., Sasako M., et al. Extended lymph node dissection for gastric cancer: Dutch gastric cancer Group. N Engl J Med 340 (1999) 908-914
39. Bozetti F. Principles of surgical radicality in the treatment of gastric cancer. Surg Oncol Clin N Am 10 (2001) 833-854
40. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 (2001) 725-730
41. Cunningham D., Jost L.M., Purkalne G., et al. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer. Ann Oncol 16 supplement 1 (2005) i22-i23
42. Earle C.C., and Maroun J.A. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 35 (1999) 1059-1064
43. Mari E., Floriani I., Tinazzi A., et al. Efficacy of adjuvant chemotherapy after curative resection of gastric cancer: a meta-analysis of published randomised trials. Ann Oncol 11 (2000) 837-843
44. Janunger K.G., Hafstrom L., and Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 168 (2002) 597-608
45. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006) 11-20
46. Siewert J.R., Fink U., Sendler A., et al. Gastric cancer. Curr Probl Surg 34 (1997) 835-839
47. Wilke H., Preusser P., Fink U., et al. Preoperative chemotherapy in locally advanced and non-resectable gastric cancer: a phase II study with etoposide, doxorubicin and cisplatin. J Clin Oncol 7 (1989) 1318-1326
48. Ott K., Sendler A., Becker K., et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 6 (2003) 159-167
49. Ajani J.A., Mansfield P.F., Janjan N., et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 22 (2004) 2774-2780
50. Lordick F., and Siewert J.R. Neoadjuvante therapie beim lokal fortgeschrittenen magenkarzinom. Onkologe 11 (2005) 640-649